

Authority

This standard has been approved by the Australian Health Workforce Ministerial Council on 31 March 2010 pursuant to the *Health Practitioner Regulation National Law (2009)* (the National Law) with approval taking effect from 1 July 2010.

Summary

The Podiatry Board of Australia has established this standard in accordance with sections 38(2) and 94 of the *Health Practitioner Regulation National Law Act 2009* (Qld).

This standard sets out the qualifications and other requirements that must be met in order for a registered podiatrist or applicant for registration as a podiatrist to be granted an endorsement under section 94 of the National Law as qualified to prescribe or supply scheduled medicines.

Scope of application

An endorsement under section 94 indicates that the registered podiatrist is qualified to administer, obtain, possess, prescribe, sell, supply or use Schedule 2, 3, 4 or 8 medicines to patients for the treatment of podiatric conditions, from a list approved by the Board.

The endorsement relates to any Schedule 2, 3, 4 or 8 medicine within the meaning of the current poisons standard under section 52D of the *Therapeutic Goods Act 1989* (Cwlth) that is used in the treatment of podiatric conditions and is listed in guidelines issued from time to time by the Podiatry Board of Australia and published on the Board's website.

Wording to appear on the Register of Podiatrists

Endorsed as qualified to administer, obtain, possess, prescribe, sell, supply or use Schedule 2, 3, 4 or 8 medicines for the treatment of podiatric conditions.

Qualifications

1. To be eligible to be granted an endorsement for scheduled medicines under section 94, an applicant for registration or a registered podiatrist must have successfully completed:
 - an approved program of study in podiatric therapeutics, or
 - a program of study determined by the Board to be substantially equivalent to an approved program of study, and

- a) a period of postqualification experience (seven years clinical experience in an appropriate setting where active prescribing is occurring and two confirmatory references of applicant exposure to patient care involving restricted drugs), or
- b) completion of web-based case studies approved by the Board (20 hours) and a specified period of supervised practice (40 sessions of supervision by an endorsed prescriber approved by the Board in an appropriate setting where active prescribing is occurring in a 12 month period).

An approved program of study is one that has been accredited by the Australia and New Zealand Podiatry Accreditation Council (ANZPAC) and approved by the Podiatry Board of Australia for the purpose of qualifying a podiatrist for a scheduled medicines endorsement under section 94 of the National Law.

A list of approved programs of study will be available on the Board's website at www.podiatryboard.gov.au.

Other requirements

Endorsed podiatrists must comply with practice guidelines on prescribing of scheduled medicines issued from time to time by the Podiatry Board of Australia and published in accordance with section 39 of the National Law on the Board's website at the following address:
www.podiatryboard.gov.au

Review

This standard for endorsement of registration applies from 1 July 2010. The Board will review this standard within three years of operation.